Abstract
Impaired insulin sensitivity, namely insulin resistance, is a metabolic and functional disorder that is often associated with the type 2 diabetes mellitus and/or obesity. Recent studies have provided compelling clues that the neuropeptide galanin is closely related to insulin sensitivity in skeletal muscle and adipose tissue of rats. This peptide may regulate glucose homeostasis and carbohydrate metabolism in peripheral tissues, as well as accelerate the translocation of glucose transporter 4 to the plasma membrane of various insulin-sensitive cells to reduce insulin resistance. Galanin plays a crucial role in inhibiting insulin secretion from pancreatic β cells to prevent hyperinsulinemia, which is a characteristic of type 2 diabetes mellitus. This review provides a comprehensive aggregation of the current literature available, bringing together data gleaned from our recent studies highlighting the role of galanin in regulating insulin sensitivity. This comprehensive role played by galanin and its relative agents in regulating insulin secretion and insulin sensitivity provides a new insight into the influence of this neuropeptides on the prevention and treatment of type 2 diabetes mellitus.
Keywords: Galanin, insulin, glucose transporter 4.
Current Protein & Peptide Science
Title:The Neuropeptide Galanin Benefits Insulin Sensitivity in Subjects with Type 2 Diabetes
Volume: 14 Issue: 8
Author(s): Penghua Fang, Mei Yu, Mingyi Shi, Biao He, Zhenwen Zhang and Ping Bo
Affiliation:
Keywords: Galanin, insulin, glucose transporter 4.
Abstract: Impaired insulin sensitivity, namely insulin resistance, is a metabolic and functional disorder that is often associated with the type 2 diabetes mellitus and/or obesity. Recent studies have provided compelling clues that the neuropeptide galanin is closely related to insulin sensitivity in skeletal muscle and adipose tissue of rats. This peptide may regulate glucose homeostasis and carbohydrate metabolism in peripheral tissues, as well as accelerate the translocation of glucose transporter 4 to the plasma membrane of various insulin-sensitive cells to reduce insulin resistance. Galanin plays a crucial role in inhibiting insulin secretion from pancreatic β cells to prevent hyperinsulinemia, which is a characteristic of type 2 diabetes mellitus. This review provides a comprehensive aggregation of the current literature available, bringing together data gleaned from our recent studies highlighting the role of galanin in regulating insulin sensitivity. This comprehensive role played by galanin and its relative agents in regulating insulin secretion and insulin sensitivity provides a new insight into the influence of this neuropeptides on the prevention and treatment of type 2 diabetes mellitus.
Export Options
About this article
Cite this article as:
Fang Penghua, Yu Mei, Shi Mingyi, He Biao, Zhang Zhenwen and Bo Ping, The Neuropeptide Galanin Benefits Insulin Sensitivity in Subjects with Type 2 Diabetes, Current Protein & Peptide Science 2013; 14 (8) . https://dx.doi.org/10.2174/1389203711209070611
DOI https://dx.doi.org/10.2174/1389203711209070611 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Vascular Factors in Late-Onset Sporadic Alzheimers Disease. Genetic and Molecular Aspects
Current Alzheimer Research Gadolinium-Contrast Toxicity in Patients with Kidney Disease: Nephrotoxicity and Nephrogenic Systemic Fibrosis
Current Drug Safety Editorial (Point-of-Care Technologies and their Global Health Applications)
Current Pharmacogenomics and Personalized Medicine Lipid Metabolism and Nutrient Partitioning Strategies
Current Drug Targets - CNS & Neurological Disorders Long-term Exposure to Cadmium in Food and Cigarette Smoke, Liver Effects and Hepatocellular Carcinoma
Current Drug Metabolism Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Editorial [Hot Topic: Inflammation in Atherosclerosis: Current Therapeutic Approaches (Executive Guest Editor: Dimitris Tousoulis)]
Current Pharmaceutical Design Fine Tuning of PPAR Ligands for Type 2 Diabetes and Metabolic Syndrome
Mini-Reviews in Medicinal Chemistry Trends in Metabolic Syndrome and Gene Networks in Human and Rodent Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Signal Pathways Mediating Antidepressant and Antipsychotic Drugs on Neuronal Cell Survival
Current Medicinal Chemistry - Central Nervous System Agents Design and Synthesis of Novel 5-Arylisoxazole-1,3,4-thiadiazole Hybrids as α-Glucosidase Inhibitors
Letters in Drug Design & Discovery Long-Term Psychosexual Development in Genetic Males Affected by Disorders of Sex Development (46,XY DSD) Reared Male or Female
Current Pediatric Reviews The Pharmacological Management of Intrahepatic Cholestasis of Pregnancy
Current Clinical Pharmacology Advanced Approaches in Insulin Delivery
Current Pharmaceutical Biotechnology Current Updates on Bone Grafting Biomaterials and Recombinant Human Growth Factors Implanted Biotherapy for Spinal Fusion: A Review of Human Clinical Studies
Current Drug Delivery Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature
Current Cardiology Reviews The Growth Hormone Secretagogue Receptor (Ghs-R)
Current Pharmaceutical Design Nitric Oxide in Normal and Preeclamptic Pregnancy
Current Pharmaceutical Biotechnology